Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

M. J. Mckeage , J. von Pawel , M. Reck , M. B. Jameson , M. A. Rosenthal , R. Sullivan , D. Gibbs , P. N. Mainwaring , M. Serke , Jérôme Lafitte , C. Chouaid (1) , L. Freitag , E. Quoix

1 ESIM - Epidémiologie des maladies infectieuses et modélisation

ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy. Patients were randomised to receive

Domaines: Santé publique et épidémiologie

M. J. Mckeage, J. von Pawel, M. Reck, M. B. Jameson, M. A. Rosenthal, et al.. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.. British Journal of Cancer, 2008, 99 (12), pp.2006-12. ⟨10.1038/sj.bjc.6604808⟩. ⟨hal-00597060⟩